3,504
Views
2
CrossRef citations to date
0
Altmetric
Editorial

Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?

ORCID Icon
 

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

W. Chen: Conceptualization, Investigation, Writing - review & editing.

Additional information

Funding

The antimicrobial resistance research in our laboratories has been supported by NRC intramural (A-base) program under the Vaccine and Emerging Infection Research Initiative (Human Health and Therapeutics) and NRC Ideation Small Team Project (National Program Office). The view expressed here is solely the responsibility of the author and does not necessarily represent the official views of NRC.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.